Taxane analogues against lung cancer: a quantitative structure-activity relationship study

Area of Science:

• Medicinal Chemistry
• Oncology
• Computational Chemistry

Background:

• Lung cancer is a leading cause of cancer death globally.
• Docetaxel, a taxane, is a key treatment for advanced non-small cell lung cancer but has side effects.
• There is a need for novel taxane derivatives with improved efficacy and safety profiles.

Purpose of the Study:

• To develop new taxane derivatives for lung cancer treatment.
• To understand the structure-activity relationships of taxane derivatives against lung cancer cells.
• To identify potential new drug candidates with enhanced anticancer properties.

Main Methods:

• Synthesized and tested four series of taxane derivatives for inhibitory activity against lung cancer cells.
• Utilized quantitative structure-activity relationship (QSAR) modeling.
• Correlated biological activity with hydrophobic and steric descriptors, focusing on MR(Y).
• Performed internal and external validation of QSAR models.

Main Results:

• A parabolic correlation between inhibitory activity and the MR(Y) descriptor was identified.
• This model suggests an optimal MR(Y) value for activity.
• Six specific compounds (3-23 to 3-28) were proposed as promising synthetic targets.
• QSAR models demonstrated robust validation through cross-validation, Q-factor, Fischer statistics, and Y-randomization.

Conclusions:

• QSAR analysis provides valuable insights into the chemical-biological interactions of taxane derivatives.
• The identified model can guide the design of novel taxane-based lung cancer therapeutics.
• Compounds 3-23 to 3-28 represent potential candidates for further development in lung cancer therapy.